GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arrowhead Pharmaceuticals Inc (LTS:0HI3) » Definitions » Short Percentage of Float

Arrowhead Pharmaceuticals (LTS:0HI3) Short Percentage of Float


View and export this data going back to 2018. Start your Free Trial

What is Arrowhead Pharmaceuticals Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Arrowhead Pharmaceuticals's Short Percentage of Float

For the Biotechnology subindustry, Arrowhead Pharmaceuticals's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arrowhead Pharmaceuticals's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arrowhead Pharmaceuticals's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Arrowhead Pharmaceuticals's Short Percentage of Float falls into.


Arrowhead Pharmaceuticals (LTS:0HI3) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arrowhead Pharmaceuticals Inc (LTS:0HI3) » Definitions » Short Percentage of Float
Comparable Companies
SWTX BHVN INSM XENE CORT FOLD IDYA PTCT RARE IOVA OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
ARWR:USA HDP1:Germany
Address
177 E. Colorado Boulevard, Suite 700, Pasadena, CA, USA, 91105
Website
https://www.arrowheadpharma.com
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.

Arrowhead Pharmaceuticals (LTS:0HI3) Headlines

No Headlines